CAU
COLL icon

Caxton Associates (UK)’s Collegium Pharmaceutical COLL Stock Holding History

Caxton Associates (UK)’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,794
Closed -$639K – 817
2025
Q4 		$639K Sell
13,794
-13,668
-50% -$572K 0.01% 451
2025
Q3 		$961K Buy
+27,462
New +$955K 0.02% 347

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Caxton Associates (UK)'s COLL Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Collegium Pharmaceutical (COLL) in Q1 2026, closing a stake of 13,794 shares — an estimated $639K sold.

Caxton Associates (UK) first reported a position in COLL in Q3 2025 and held it in 2 quarters. The position peaked at $961K in Q3 2025. 267 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Collegium Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 13,794 Collegium Pharmaceutical shares in Q1 2026, an estimated $639K.
  • Caxton Associates (UK) first reported a position in Collegium Pharmaceutical in Q3 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Collegium Pharmaceutical position peaked at $961K in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.